source
- Setara Biosciences raises $90 million Series A to advance Jazz-spun rare disease programsSetara Biosciences has been created to focus on a set of rare-disease assets that Jazz Pharmaceuticals retained after acquiring Actio Biosciences. The new company secured $90 million in Series A f…
- AstraZeneca launches $1.5 billion annual cost-saving plan to offset late-stage trial setbacksAstraZeneca announced a new cost‑saving initiative targeting $1.5 billion of annual expenses. The move follows a series of late‑stage clinical trial failures that have pressured the company's pipe…